Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials
Progress in Cardiovascular Diseases · 2024-07 · 85 · 45-53
DOI: 10.1016/j.pcad.2024.04.001 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Progress in Cardiovascular Diseases, 2024-07. Verfasst von Vikash Jaiswal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Research, Larkin Community Hospital, South Miami, FL, USA. Electronic address: vikash29jaxy@gmail.com. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hormone Replacement Therapy, Hypogonadism, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The Cardiovascular safety of testosterone replacement therapy (TRT) among men with hypogonadism is not well established to date. Hence, we sought to evaluate the cardiovascular disease (CVD) outcomes among patients receiving testosterone therapy by using all recently published randomized controlled trials. METHODS: We performed a systematic literature search on PubMed, EMBASE, and Clinicaltrial.gov for relevant randomized controlled trials (RCTs) from inception until September 30th, 2023. RESULTS: A total of 30 randomized trials with 11,502 patients were included in the final analysis. The mean age was ranging from 61.61 to 61.82 years. Pooled analysis of primary and secondary outcomes showed that the incidence of any CVD events (OR, 1.12 (95%CI: 0.77-1.62), P = 0.55), stroke (OR, 1.01 (95%CI: 0.68-1.51), P = 0.94), myocardial infarction (OR, 1.05 (95%CI: 0.76-1.45), P = 0.77), all-cause mortality (OR, 0.94 (95%CI: 0.76-1.17), P = 0.57), and CVD mortality (OR, 0.87 (95%CI: 0.65-1.15), P = 0.31) was comparable between TRT and placebo groups. CONCLUSION: Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Research, Larkin Community Hospital, South Miami, FL, USA. Electronic address: vikash29jaxy@gmail.com.
- Department of Internal Medicine, Crozer Chester Medical Center, Upland, PA, USA.
- Department of Internal Medicine, Nuvance Health, Poughkeepsie, NY, USA.
- Department of Internal Medicine, University of Texas Rio Grande Valley, Weslaco, TX, USA.
- North Bengal Medical College and Hospital, India.
- Department of Internal Medicine, UPMC, Harrisburg, PA, USA.
Zitieren
APA
Jaiswal, V., Sawhney, A., Nebuwa, C., Borra, V., Deb, N., Halder, A., Rajak, K., Jha, M., Wajid, Z., Thachil, R., Bandyopadhyay, D., Mattumpuram, J., & Lavie, C. J. (2024). Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. Progress in Cardiovascular Diseases, 85, 45-53. https://doi.org/10.1016/j.pcad.2024.04.001
Vancouver
Jaiswal V, Sawhney A, Nebuwa C, Borra V, Deb N, Halder A, et al. Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. Progress in Cardiovascular Diseases. 2024;85:45-53. doi:10.1016/j.pcad.2024.04.001
BibTeX
@article{Jaiswal2024,
author = {Jaiswal, Vikash and Sawhney, Aanchal and Nebuwa, Chikodili and Borra, Vamsikalyan and Deb, Novonil and Halder, Anupam and Rajak, Kripa and Jha, Mayank and Wajid, Zarghoona and Thachil, Rosy and Bandyopadhyay, Dhrubajyoti and Mattumpuram, Jishanth and Lavie, Carl J},
title = {Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials},
journal = {Progress in Cardiovascular Diseases},
year = {2024},
volume = {85},
pages = {45--53},
doi = {10.1016/j.pcad.2024.04.001}
}
EUVIMED